Single-center, open-label study of GP2017 in healthy male subjects

Trial Profile

Single-center, open-label study of GP2017 in healthy male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2017 Results from this trial were presented at the American College of Rheumatology (ACR) Annual Meeting according to a Sandoz media release.
    • 25 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top